300110 华仁药业
已收盘 08-03 15:00:00
资讯
新帖
简况
股市必读：华仁药业新发布《关于收到青岛证监局对公司采取责令改正监管措施决定的公告》
证券之星 · 08-03 03:28
股市必读：华仁药业新发布《关于收到青岛证监局对公司采取责令改正监管措施决定的公告》
华仁药业被责令改正，涉内控等违规
蓝鲸财经 · 07-31
华仁药业被责令改正，涉内控等违规
华仁药业的“双重困局”：旧账未清、新诉重审，资产缩水近半暴露内控危机
新浪证券 · 07-31
华仁药业的“双重困局”：旧账未清、新诉重审，资产缩水近半暴露内控危机
华仁药业：上半年业绩情况请关注公司计划于2026年8月27日披露的2026年半年度报告
证券之星 · 07-29
华仁药业：上半年业绩情况请关注公司计划于2026年8月27日披露的2026年半年度报告
股市必读：华仁药业（300110）7月24日董秘有最新回复
证券之星 · 07-27
股市必读：华仁药业（300110）7月24日董秘有最新回复
华仁药业：持续推进相关应收款项追偿
证券之星 · 07-24
华仁药业：持续推进相关应收款项追偿
华仁药业：积极布局饮料、化妆品、健康饮品等大健康产品线
证券之星 · 07-24
华仁药业：积极布局饮料、化妆品、健康饮品等大健康产品线
华仁药业：截至2026年7月20日，公司股东总户数约为3.96万户
证券之星 · 07-23
华仁药业：截至2026年7月20日，公司股东总户数约为3.96万户
华仁药业：公司将基于最大化挽回损失的原则，持续积极跟进债务化解进度
证券之星 · 07-23
华仁药业：公司将基于最大化挽回损失的原则，持续积极跟进债务化解进度
华仁药业：已将常态化梳理应收款项、加快应收处置回款、持续优化资产结构等纳入重点工作安排
证券之星 · 07-16
华仁药业：已将常态化梳理应收款项、加快应收处置回款、持续优化资产结构等纳入重点工作安排
华仁药业（300110）披露重大诉讼进展公告，7月15日股价上涨1.81%
证券之星 · 07-15
华仁药业（300110）披露重大诉讼进展公告，7月15日股价上涨1.81%
华仁药业：关于股份回购计划
证券之星 · 07-14
华仁药业：关于股份回购计划
华仁药业：截至2026年7月10日，公司股东总户数约为3.90万户
证券之星 · 07-14
华仁药业：截至2026年7月10日，公司股东总户数约为3.90万户
华仁药业：已制定《华仁药业股份有限公司市值管理制度》
证券之星 · 07-06
华仁药业：已制定《华仁药业股份有限公司市值管理制度》
华仁药业（300110）披露聘任副总裁公告，7月2日股价上涨0.77%
证券之星 · 07-02
华仁药业（300110）披露聘任副总裁公告，7月2日股价上涨0.77%
华仁药业：2025年度腹膜透析液销量达3,480.80万袋
证券之星 · 06-25
华仁药业：2025年度腹膜透析液销量达3,480.80万袋
华仁药业：截至2026年6月18日，公司股东总户数约为3.83万户
证券之星 · 06-24
华仁药业：截至2026年6月18日，公司股东总户数约为3.83万户
华仁药业：截至2026年6月10日，公司股东总户数约为3.81万户
证券之星 · 06-17
华仁药业：截至2026年6月10日，公司股东总户数约为3.81万户
股市必读：华仁药业(300110)股东户数3.83万户，较上期减少1.79%
证券之星 · 06-01
股市必读：华仁药业(300110)股东户数3.83万户，较上期减少1.79%
华仁药业(300110)5月20日股东户数3.83万户，较上期减少1.79%
证券之星 · 05-29
华仁药业(300110)5月20日股东户数3.83万户，较上期减少1.79%
加载更多
公司概况
公司名称：
华仁药业股份有限公司
所属行业：
医药制造业
上市日期：
2010-08-25
主营业务：
华仁药业股份有限公司的主营业务是原料药、制剂、医疗器械、医用包材、大健康产品的研发、生产、销售。公司的主要产品是基础输液、治疗制剂、腹透液。公司先后获得“全国AAA级信用企业”、“中国化学制药行业工业企业综合实力百强”、“中国医药工业百强”等荣誉。
发行价格：
13.99
{"stockData":{"symbol":"300110","market":"SZ","secType":"STK","nameCN":"华仁药业","latestPrice":2.72,"timestamp":1785740637000,"preClose":2.68,"halted":0,"volume":22639291,"delay":0,"changeRate":0.0149,"floatShares":1181000000,"shares":1182000000,"eps":-0.3917,"marketStatus":"已收盘","change":0.04,"latestTime":"08-03 15:00:00","open":2.67,"high":2.72,"low":2.66,"amount":61036900,"amplitude":0.0224,"askPrice":2.72,"askSize":2136,"bidPrice":2.71,"bidSize":3659,"shortable":0,"etf":0,"ttmEps":-0.3917,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1785807000000},"marketStatusCode":5,"adr":0,"adjPreClose":2.68,"symbolType":"stock","openAndCloseTimeList":[[1785720600000,1785727800000],[1785733200000,1785740400000]],"highLimit":2.95,"lowLimit":2.41,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":1182212982,"isCdr":false,"pbRate":3.71,"roa":"--","roe":"1.89%","epsLYR":-0.3916,"committee":-0.043077,"marketValue":3216000000,"turnoverRate":0.0192,"status":0,"floatMarketCap":3213000000},"requestUrl":"/m/hq/s/300110","defaultTab":"news","newsList":[{"id":"2656343221","title":"股市必读：华仁药业新发布《关于收到青岛证监局对公司采取责令改正监管措施决定的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2656343221","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2656343221?lang=zh_cn&edition=full","pubTime":"2026-08-03 03:28","pubTimestamp":1785698892,"startTime":"0","endTime":"0","summary":"截至2026年7月31日收盘，华仁药业报收于2.68元，上涨0.75%，换手率1.63%，成交量19.28万手，成交额5159.4万元。公司公告汇总：华仁药业于7月31日收到青岛证监局责令改正监管措施决定，涉及贸易业务内控、合同管理、工程验收、对外投资及内幕信息知情人档案等多项问题，要求30日内提交书面整改报告。青岛证监局决定对公司采取责令改正的行政监管措施，要求公司30日内提交书面整改报告，并对公司治理、内部控制、追责问责等方面提出整改要求。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080300001392.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0102","BK0239","300110"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655350523","title":"华仁药业被责令改正，涉内控等违规","url":"https://stock-news.laohu8.com/highlight/detail?id=2655350523","media":"蓝鲸财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2655350523?lang=zh_cn&edition=full","pubTime":"2026-07-31 18:38","pubTimestamp":1785494306,"startTime":"0","endTime":"0","summary":"蓝鲸新闻7月31日讯，近日，青岛证监局发布行政监管措施决定书，剑指华仁药业股份有限公司。决定书显示，华仁药业存在以下情形：贸易业务内部控制机制不健全、内部制度执行不到位、合同未全面履行或监控不当；个别销售业务缺少书面合同，个别子公司合同签署不规范；个别工程项目竣工验收报审表不完整；个别对外投资管理不规范；部分知情人未对内幕信息知情人档案表进行确认等。以上行为违反了《企业内部控制基本规范》《上市公司治理准则》《企业内部控制应用指引》《关于上市公司内幕信息知情人登记管理制度的规定》的相关规定。针对上述违法行为，青岛证监局对华仁药业采取责令改正的行政监管措施。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1785491569003022820","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK0102","300110","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655332851","title":"华仁药业的“双重困局”：旧账未清、新诉重审，资产缩水近半暴露内控危机","url":"https://stock-news.laohu8.com/highlight/detail?id=2655332851","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2655332851?lang=zh_cn&edition=full","pubTime":"2026-07-31 13:58","pubTimestamp":1785477480,"startTime":"0","endTime":"0","summary":"旧账未清、新诉缠身，华仁药业的修复逻辑正遭遇严峻考验。02股权纠纷发回重审：并购后遗症叠加，管理层问责缺位与应收账款旧账并行的，是一桩延续多年的股权收购纠纷。2021年，子公司曲江华仁收购安徽恒星制药100%股权，交易对手随后起诉要求支付2.56亿元业绩承诺尾款及违约金，合计2.84亿元，并要求上市公司承担连带责任。曲江华仁则反诉请求撤销协议、返还5.44亿元转让款及资金占用费。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/aigcy/2026-07-31/doc-iniksnxm4558734.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["300110","BK0102","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655898737","title":"华仁药业：上半年业绩情况请关注公司计划于2026年8月27日披露的2026年半年度报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2655898737","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2655898737?lang=zh_cn&edition=full","pubTime":"2026-07-29 20:48","pubTimestamp":1785329321,"startTime":"0","endTime":"0","summary":"证券之星消息，华仁药业(300110)07月29日在投资者关系平台上答复投资者关心的问题。投资者提问：口口声声提升业绩回馈投资者，上半年业绩如何？为什么没预告？华仁药业回复：您好，规则未强制要求创业板上市公司发布半年度业绩预告，上半年业绩情况请您关注公司计划于2026年8月27日披露的2026年半年度报告。感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072900037866.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0102","300110"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654064997","title":"股市必读：华仁药业（300110）7月24日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2654064997","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654064997?lang=zh_cn&edition=full","pubTime":"2026-07-27 02:10","pubTimestamp":1785089425,"startTime":"0","endTime":"0","summary":"截至2026年7月24日收盘，华仁药业报收于2.59元，下跌3.72%，换手率1.91%，成交量22.56万手，成交额5932.96万元。董秘最新回复投资者： 你们现在对国药药材提起诉讼是不是太晚了？公司将持续压实各级管理人员经营主体责任，切实维护全体股东合法权益。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072700001033.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300110","BK0102","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653827290","title":"华仁药业：持续推进相关应收款项追偿","url":"https://stock-news.laohu8.com/highlight/detail?id=2653827290","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653827290?lang=zh_cn&edition=full","pubTime":"2026-07-24 20:48","pubTimestamp":1784897310,"startTime":"0","endTime":"0","summary":"证券之星消息，华仁药业07月24日在投资者关系平台上答复投资者关心的问题。公司将持续压实各级管理人员经营主体责任，切实维护全体股东合法权益。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072400039496.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300110","BK0239","BK0102"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653717082","title":"华仁药业：积极布局饮料、化妆品、健康饮品等大健康产品线","url":"https://stock-news.laohu8.com/highlight/detail?id=2653717082","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653717082?lang=zh_cn&edition=full","pubTime":"2026-07-24 20:48","pubTimestamp":1784897305,"startTime":"0","endTime":"0","summary":"证券之星消息，华仁药业(300110)07月24日在投资者关系平台上答复投资者关心的问题。投资者提问：饮料，化妆品为什么几年的销量都占比很小，你们以怎样的方式在销售工作有没有专业队伍还是在闭门造车？华仁药业回复：您好，公司积极布局饮料、化妆品、健康饮品等大健康产品线，主要采用线上线下相结合的模式开展销售。该系列产品目前销售收入占比还较小，后续公司将加强品牌建设和渠道建设，持续推进大健康产品线上、线下销售渠道的开发与推广。感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072400039490.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300110","BK0102","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653723832","title":"华仁药业：截至2026年7月20日，公司股东总户数约为3.96万户","url":"https://stock-news.laohu8.com/highlight/detail?id=2653723832","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653723832?lang=zh_cn&edition=full","pubTime":"2026-07-23 21:00","pubTimestamp":1784811628,"startTime":"0","endTime":"0","summary":"证券之星消息，华仁药业(300110)07月22日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘 你好 衷心感谢你们不厌其烦回答投资者的提问。请问贵公司2026年7月20日A股股东人数是多少？谢谢华仁药业回复：尊敬的投资者您好，截至2026年7月20日，公司股东总户数约为3.96万户。感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072300045885.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300110","BK0239","BK0102"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653723874","title":"华仁药业：公司将基于最大化挽回损失的原则，持续积极跟进债务化解进度","url":"https://stock-news.laohu8.com/highlight/detail?id=2653723874","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653723874?lang=zh_cn&edition=full","pubTime":"2026-07-23 21:00","pubTimestamp":1784811627,"startTime":"0","endTime":"0","summary":"证券之星消息，华仁药业(300110)07月22日在投资者关系平台上答复投资者关心的问题。投资者提问：公司是否对国药药材提起诉讼？不是说最小损失原则减少损失化解债务吗？是否可能收回，对方有执行标的吗？华仁药业回复：尊敬的投资者您好，公司将基于最大化挽回损失的原则，持续积极跟进债务化解进度。公司将结合国药药材履约情况，积极合理配合利用司法手段，最大限度确保债务化解执行质量及效果，最大程度挽回损失，最大程度维护公司及全体股东的合法权益。感谢您的关注。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072300045882.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0102","BK0239","300110"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651428204","title":"华仁药业：已将常态化梳理应收款项、加快应收处置回款、持续优化资产结构等纳入重点工作安排","url":"https://stock-news.laohu8.com/highlight/detail?id=2651428204","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651428204?lang=zh_cn&edition=full","pubTime":"2026-07-16 20:51","pubTimestamp":1784206283,"startTime":"0","endTime":"0","summary":"证券之星消息，华仁药业07月15日在投资者关系平台上答复投资者关心的问题。请问管理层在制定市值管理方案时，有无将\"加快诉讼回款、加大坏账核销/冲回、优化资产质量\"作为提升估值的重要手段并向市场主动披露相关规划？","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071600038080.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300110","BK0102","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651459532","title":"华仁药业（300110）披露重大诉讼进展公告，7月15日股价上涨1.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2651459532","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651459532?lang=zh_cn&edition=full","pubTime":"2026-07-15 17:31","pubTimestamp":1784107917,"startTime":"0","endTime":"0","summary":"截至2026年7月15日收盘，华仁药业报收于2.82元，较前一交易日上涨1.81%，最新总市值为33.34亿元。华仁药业于近日披露《关于重大诉讼的进展公告》。本案系陕西省高级人民法院指令西安市中级人民法院重新立案审理，案号为陕01民初208号，目前尚未开庭。此前相关案件已被驳回起诉，原告上诉后获指令继续审理。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071500033804.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300110","BK0102","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651510638","title":"华仁药业：关于股份回购计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2651510638","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651510638?lang=zh_cn&edition=full","pubTime":"2026-07-14 20:53","pubTimestamp":1784033594,"startTime":"0","endTime":"0","summary":"证券之星消息，华仁药业(300110)07月14日在投资者关系平台上答复投资者关心的问题。投资者提问：别的公司都在回购你们为什么不回购？请解释一下具体原因股价很高吗？你们为什么会在4块8收购，为什么不回购？华仁药业回复：尊敬的投资者您好，关于股份回购计划，公司将根据市场情况、财务状况及发展战略等多方面因素进行综合考虑，作出科学合理的决策，维护广大投资者利益。如有相关回购计划，公司将严格遵守相关规定，及时履行信息披露义务。感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071400046429.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300110","BK0239","BK0102"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651063811","title":"华仁药业：截至2026年7月10日，公司股东总户数约为3.90万户","url":"https://stock-news.laohu8.com/highlight/detail?id=2651063811","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651063811?lang=zh_cn&edition=full","pubTime":"2026-07-14 20:53","pubTimestamp":1784033592,"startTime":"0","endTime":"0","summary":"证券之星消息，华仁药业(300110)07月14日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘 你好 衷心感谢你们不厌其烦回答投资者的提问。请问贵公司2026年7月10日A股股东人数是多少？谢谢华仁药业回复：尊敬的投资者您好，截至2026年7月10日，公司股东总户数约为3.90万户。感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071400046424.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0102","300110"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649862489","title":"华仁药业：已制定《华仁药业股份有限公司市值管理制度》","url":"https://stock-news.laohu8.com/highlight/detail?id=2649862489","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649862489?lang=zh_cn&edition=full","pubTime":"2026-07-06 20:51","pubTimestamp":1783342284,"startTime":"0","endTime":"0","summary":"证券之星消息，华仁药业07月06日在投资者关系平台上答复投资者关心的问题。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070600034930.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300110","BK0102","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648619689","title":"华仁药业（300110）披露聘任副总裁公告，7月2日股价上涨0.77%","url":"https://stock-news.laohu8.com/highlight/detail?id=2648619689","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648619689?lang=zh_cn&edition=full","pubTime":"2026-07-02 23:19","pubTimestamp":1783005551,"startTime":"0","endTime":"0","summary":"截至2026年7月2日收盘，华仁药业报收于2.62元，较前一交易日上涨0.77%，最新总市值为30.97亿元。该股当日开盘2.58元，最高2.73元，最低2.58元，成交额达7124.13万元，换手率为2.28%。华仁药业股份有限公司于2026年7月2日召开第八届董事会第十五次（临时）会议，审议通过聘任张信中先生为公司副总裁的议案。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070200042885.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300110","BK0239","BK0102"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646038288","title":"华仁药业：2025年度腹膜透析液销量达3,480.80万袋","url":"https://stock-news.laohu8.com/highlight/detail?id=2646038288","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646038288?lang=zh_cn&edition=full","pubTime":"2026-06-25 20:52","pubTimestamp":1782391962,"startTime":"0","endTime":"0","summary":"华仁药业回复：尊敬的投资者您好，公司腹膜透析液是国内首家上市的非PVC包装腹膜透析产品，不含增塑剂，产品质量稳定，超滤水平优于市场同类产品，已取得23个品规的腹膜透析液药品批准文号，其中8个品规通过或视同通过一致性评价，实现现有腹膜透析液全品种过评。2025年度，公司腹膜透析液产品销量达3,480.80万袋，同比增长40.16%，实现销售收入4.60亿元，同比增长32.21%，保持强劲增长态势。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062500041776.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0102","BK0239","300110"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645881583","title":"华仁药业：截至2026年6月18日，公司股东总户数约为3.83万户","url":"https://stock-news.laohu8.com/highlight/detail?id=2645881583","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645881583?lang=zh_cn&edition=full","pubTime":"2026-06-24 20:51","pubTimestamp":1782305510,"startTime":"0","endTime":"0","summary":"证券之星消息，华仁药业(300110)06月23日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你好！请问一下截止到2026.06.18的股东数是多少？谢谢啊！！华仁药业回复：尊敬的投资者您好，截至2026年6月18日，公司股东总户数约为3.83万户。感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062400042049.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300110","BK0102","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644746257","title":"华仁药业：截至2026年6月10日，公司股东总户数约为3.81万户","url":"https://stock-news.laohu8.com/highlight/detail?id=2644746257","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644746257?lang=zh_cn&edition=full","pubTime":"2026-06-17 20:48","pubTimestamp":1781700501,"startTime":"0","endTime":"0","summary":"证券之星消息，华仁药业(300110)06月16日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你好！请问一下截止到2026.06.10的股东数是多少？谢谢！！！！华仁药业回复：尊敬的投资者您好，截至2026年6月10日，公司股东总户数约为3.81万户。感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061700039258.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0102","300110","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640089985","title":"股市必读：华仁药业(300110)股东户数3.83万户，较上期减少1.79%","url":"https://stock-news.laohu8.com/highlight/detail?id=2640089985","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640089985?lang=zh_cn&edition=full","pubTime":"2026-06-01 04:26","pubTimestamp":1780259172,"startTime":"0","endTime":"0","summary":"截至2026年5月29日收盘，华仁药业报收于2.8元，上涨0.0%，换手率1.38%，成交量16.31万手，成交额4580.01万元。来自股本股东变化：截至5月20日股东户数环比下降1.79%，筹码集中度有所提升。股本股东变化股东户数变动近日华仁药业披露，截至2026年5月20日公司股东户数为3.83万户，较5月8日减少700.0户，减幅为1.79%。户均持股数量由上期的3.03万股增加至3.09万股，户均持股市值为9.07万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060100001878.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300110","BK0239","BK0102"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639626542","title":"华仁药业(300110)5月20日股东户数3.83万户，较上期减少1.79%","url":"https://stock-news.laohu8.com/highlight/detail?id=2639626542","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639626542?lang=zh_cn&edition=full","pubTime":"2026-05-29 17:52","pubTimestamp":1780048348,"startTime":"0","endTime":"0","summary":"证券之星消息，近日华仁药业披露，截至2026年5月20日公司股东户数为3.83万户，较5月8日减少700.0户，减幅为1.79%。在化学制药行业个股中，华仁药业股东户数高于行业平均水平，截至5月20日，化学制药行业平均股东户数为3.56万户。从股价来看，2026年5月8日至2026年5月20日，华仁药业区间跌幅为4.85%，在此期间股东户数减少700.0户，减幅为1.79%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052900033407.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0102","300110","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1785790990079,"stockEarnings":[{"period":"1week","weight":0.0149},{"period":"1month","weight":0.0303},{"period":"3month","weight":-0.1365},{"period":"6month","weight":-0.1807},{"period":"1year","weight":-0.2568},{"period":"ytd","weight":-0.1365}],"compareEarnings":[{"period":"1week","weight":-0.0126},{"period":"1month","weight":-0.0579},{"period":"3month","weight":-0.0736},{"period":"6month","weight":-0.0713},{"period":"1year","weight":0.0701},{"period":"ytd","weight":-0.0401}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"华仁药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"39600人(较上一季度增加1.54%)","perCapita":"29827股","listingDate":"2010-08-25","address":"山东省青岛市崂山区高科技工业园株洲路187号","registeredCapital":"118221万元","survey":" 华仁药业股份有限公司的主营业务是原料药、制剂、医疗器械、医用包材、大健康产品的研发、生产、销售。公司的主要产品是基础输液、治疗制剂、腹透液。公司先后获得“全国AAA级信用企业”、“中国化学制药行业工业企业综合实力百强”、“中国医药工业百强”等荣誉。","listedPrice":13.99},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"华仁药业(300110)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供华仁药业(300110)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"华仁药业,300110,华仁药业股票,华仁药业股票老虎,华仁药业股票老虎国际,华仁药业行情,华仁药业股票行情,华仁药业股价,华仁药业股市,华仁药业股票价格,华仁药业股票交易,华仁药业股票购买,华仁药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"华仁药业(300110)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供华仁药业(300110)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}